Captisol - Covid was Ligand Pharmaceuticals’s largest product and service line in fiscal 2022, bringing in $88.07M of $196.25M (45%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|---|
| Captisol - Covid | — | $85.39M | $140.83M | $88.07M | |||
| Royalties | — | — | — | — | |||
| Promacta | $14.19M | — | — | — | |||
| Royalty, Promacta | — | — | — | — | |||
| Captisol | $31.49M | — | — | — | |||
| Material Sales | — | — | — | — | |||
| Kyprolis | $25.05M | $25.16M | $27.47M | $30.12M | |||
| Royalty, Kyprolis | — | — | — | — | |||
| Captisol - Core | — | $24.57M | $23.42M | $16.43M | |||
| Contract Revenue & Other Income | — | — | — | $18.84M | |||
| License Fees | $6.20M | $119.00K | $634.00K | — | |||
| Milestone | $17.17M | $5.22M | $17.58M | — | |||
| Milestones | — | — | — | — | |||
| Teriparatide Injection | — | — | $5.26M | $15.79M | |||
| Service Revenue | $16.78M | $9.33M | $3.74M | — | |||
| Evomela | $5.17M | $6.38M | $10.08M | $10.20M | |||
| Royalty, Evomela | — | — | — | — | |||
| Rylaze | — | — | $2.42M | $8.80M | |||
| License Fees Milestones & Other Product Other | $1.67M | $5.14M | $6.41M | — | |||
| Other | — | — | — | $6.55M | |||
| Royalty Other | $2.57M | $2.26M | $3.70M | — | |||
| Royalty, Other | — | — | — | — | |||
| Vaxneuvance | — | — | — | $1.08M | |||
| Income From Financial Royalty Assets | — | — | — | $385.00K | |||
| Total | $120.28M | $163.56M | $241.54M | $196.25M |
Ligand Pharmaceuticals brought in $196.25M from its 10 product and service lines in fiscal 2022, the year ended December 31, 2022. Ligand Pharmaceuticals regrouped these lines after fiscal 2021, so the total does not compare directly with that year's $241.54M. Captisol - Covid was the largest at $88.07M (44.9%), ahead of Kyprolis at $30.12M (15.3%) and Contract Revenue & Other Income at $18.84M (9.6%). The other seven lines brought in $59.23M combined.
Compared with fiscal 2021, Rylaze grew fastest, up 263.5% to $8.80M, while Captisol - Covid fell the most, down 37.5% to $88.07M.
Ligand Pharmaceuticals began breaking out Captisol - Covid in fiscal 2020, Captisol - Core in fiscal 2020, Contract Revenue & Other Income in fiscal 2022 and Teriparatide Injection in fiscal 2021. Ligand Pharmaceuticals stopped reporting Captisol ($31.49M in fiscal 2019), Milestone ($17.58M in fiscal 2021), Promacta ($14.19M in fiscal 2019) and four others as separate lines.
Ligand Pharmaceuticals (LGND) reports its revenue by product and service. In fiscal 2022, Captisol - Covid was its largest product and service line, bringing in $88.07M (44.9% of the total), followed by Kyprolis at $30.12M (15.3%).
Captisol - Covid was Ligand Pharmaceuticals' largest product and service line in fiscal 2022, bringing in $88.07M, or 44.9% of the $196.25M total across its 10 product and service lines.
Every figure comes from Ligand Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Ligand Pharmaceuticals gives it, and years follow its fiscal calendar.
Ligand Pharmaceuticals' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.